Fosamax and Osteonecrosis of the Jaw: A Review of Causation and Risk Factors

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy of General Health Information and Its Evolution

The legacy of general health and science information has long served as a foundation for public understanding of medical risks and therapeutic benefits. Within this broad context, the dissemination of knowledge regarding pharmaceutical interventions has been a key component, enabling individuals to make informed decisions about their well-being. As this heritage evolved, it naturally expanded to encompass more specialized areas of clinical concern, including the long-term effects of specific drug classes. One such area of focus has been the relationship between bisphosphonate therapy, commonly prescribed for bone density management, and rare but serious adverse events. This progression from general health literacy to targeted risk awareness represents a logical maturation of the informational landscape. Consequently, the same principles that guided earlier public health communications now apply to more nuanced discussions of exposure and outcome. This transition is particularly relevant when considering occupational settings, where sustained contact with pharmaceutical compounds or their manufacturing byproducts may present distinct risk profiles. The shift from a patient-centered, therapeutic context to an occupational exposure concern requires careful delineation of how legacy knowledge can be adapted to address workplace safety. Thus, the bridge from general health information to the specific query of Fosamax-associated osteonecrosis of the jaw risk is built upon this foundation of evolving medical awareness.

Bridging General Knowledge to Fosamax-Specific Risks

Building on the legacy of general health information, the specific inquiry into Fosamax (alendronate) and its association with osteonecrosis of the jaw (ONJ) represents a focused application of that foundational knowledge. Fosamax is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its pharmacological action involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a recognized adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed necrotic bone in the maxillofacial region that can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation often involves pain, swelling, and non-healing extraction sockets. Diagnosis is typically based on clinical examination and imaging, with a focus on identifying exposed bone persisting for more than eight weeks in the absence of radiation therapy.

Mechanistic Pathways and Risk Factors

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated but are believed to involve the drug's potent inhibition of osteoclast activity, which suppresses bone turnover. This suppression may impair the jawbone's ability to remodel and repair microdamage, particularly after dental procedures or in the presence of infection. A multiscale characterization of jawbone has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/). The jawbone's high vascularity and constant mechanical stress may make it uniquely susceptible to this adverse effect. The risk of ONJ increases with duration of bisphosphonate exposure. Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a subset of patients had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Causation Considerations and Label Warnings

Regarding causation considerations for affected patients, the adequacy of warnings in the prescribing information is a key issue. The label for Fosamax includes a specific warning under section 5.4 titled "Osteonecrosis of the Jaw," which states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also notes that discontinuation of bisphosphonate treatment may reduce the risk for ONJ in patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label does not specify a precise timeline for risk reduction after discontinuation. The optimal duration of Fosamax use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use is considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The timeline between exposure and documented harm is variable. In a cohort study among cancer-free female patients aged 40-89 with or at risk for osteoporosis in the United Kingdom Clinical Practice Research Datalink, ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This suggests a cumulative dose-response relationship, with longer exposure conferring greater risk. For patients who develop severe symptoms, the label advises discontinuation of Fosamax, and most patients had relief of symptoms after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Summary and Clinical Implications

In summary, the medical literature establishes a causal association between Fosamax use and ONJ, with risk factors including duration of therapy, invasive dental procedures, and concomitant medications. The warnings in the prescribing information address this risk, but the timeline for harm can extend from months to years of exposure. Affected patients should consider dental evaluation before initiating bisphosphonate therapy and discuss the risks and benefits of continued use with their healthcare provider.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate) is a bisphosphonate medication that inhibits bone resorption, increasing bone mass and reducing fracture risk. It is used for osteoporosis and Paget's disease of bone. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

What is osteonecrosis of the jaw (ONJ) and how is it linked to Fosamax?

ONJ is a condition of exposed necrotic bone in the jaw, often associated with dental procedures. Fosamax and other bisphosphonates can cause ONJ by suppressing bone turnover, impairing healing. Risk increases with longer use. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer, chemotherapy, corticosteroids, poor oral hygiene, and longer duration of bisphosphonate therapy. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1)

How long does it take for ONJ to develop after starting Fosamax?

Onset can vary from one day to several months. A study found risk increased after 2-3 years of treatment, with higher risk after 10 years. (https://pubmed.ncbi.nlm.nih.gov/39400702/)

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.